---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027209"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-06-04T13:00:32+00:00"
generated_at: "2026-06-04T13:01:24.379291+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Lipocine to host virtual KOL event on LPCN 1154 for postpartum depression on June 12, 2026

## Summary
- Virtual KOL event focused on unmet needs in postpartum depression and clinical profile of LPCN 1154 (oral brexanolone).
- Event scheduled for June 12, 2026 at 11:00 AM ET; advance registration required.
- LPCN 1154 Phase 3 trial showed efficacy in subgroup analysis excluding outlier site; 100% dosing completion.
- PPD affects ~1 in 5 U.S. women; annual economic burden estimated at $14.2 billion.

## SEC filing metadata
- accession: 0001493152-26-027209
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-06-04T13:00:32+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226027209/0001493152-26-027209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226027209/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027209
- JSON: https://secwatch.observer/filing/0001493152-26-027209.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027209.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.